Matthias Alder - Oct 1, 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Executive Officer, Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Oct 1, 2023
Transactions value $
$0
Form type
4
Date filed
10/3/2023, 04:36 PM
Previous filing
Sep 22, 2023
Next filing
Dec 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GANX Common Stock Options Exercise +825 +14.1% 6.68K Oct 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Restricted Stock Units Options Exercise $0 -825 -8.33% $0.00 9.08K Oct 1, 2023 Common Stock 825 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.